HOME EDITORIAL BOARD CONTACT US SUBSCRIPTION AUTHORS INDEX AUTHORS INSTRUCTIONS SUPPLEMENTARY DATA




2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1999
   
 VOLUME 15 - NUMBER 1
/ January - March 2013

 
Safety and Efficacy of Lopinavir/Ritonavir during Pregnancy: A Systematic Review
Mary V. Pasley, Marisol Martinez, Ashwaq Hermes, Ronald d’Amico and Angela Nilius |Full Article in PDF|
AbbVie Inc., North Chicago, USA
 
Abstract

The co-formulated, ritonavir-boosted protease inhibitor lopinavir is a frequently used component of HAART for treatment of HIV-infected women during pregnancy and prevention of mother-to-child transmission. We performed a systematic review to assess the effects of lopinavir/ritonavir on maternal and infant clinical and safety outcomes in HIV-infected pregnant women. PubMed, EMBASE, and select congresses were searched for studies published through May 31, 2012. Studies were selected that included HIV-infected pregnant mothers treated with a lopinavir/ritonavir-based regimen and described relevant maternal and infant outcomes. Ten articles or presentations describing nine studies were identified, comprising 2,675 lopinavir/ritonavir-treated women. In studies reporting HIV-1 RNA at delivery, HIV-1 RNA < 200 to < 1,000 copies/ml was achieved in 64-97% of subjects. Preterm delivery (< 37 weeks gestation) rates ranged from 8.3 to 25%; low birth weight (< 2,500 g) rates ranged from 11 to 20.3%. In one study, preterm delivery rates and low birth weight were similar between women who received standard or increased doses of lopinavir/ritonavir. In five studies reporting stillbirths and live births, 38 stillbirths occurred versus 2,058 live births (1.8%) among women receiving lopinavir/ritonavir. In eight studies reporting mother-to-child transmission at different time points, rates ranged from 0 to 3.3% and appeared to be similar in the one study comparing pregnant women who received standard or higher doses of lopinavir/ritonavir. The results from this systematic review suggest no unique safety or efficacy concerns with use of standard dose lopinavir/ritonavir as part of HAART in pregnant women.

 
Key words:
AIDS. Combination antiretroviral therapy. HIV. Lopinavir. Mother-to-child transmission. Pregnancy. Ritonavir.
 
Date: 04/12/2016
ISSN: 1698-6997
 
unsubscribe 

LOGIN 
Not a member?
REGISTER 

Editor's access. 



I National Conference of the GEHEP of SEIMC (Abstract book)
PERMANYER PUBLICATIONS
Mallorca, 310
08037 Barcelona - Spain
Phone: +34 93 207 59 20
Fax: +34 93 457 66 42
www.permanyer.com


 
© 2016 Permanyer Publications - Legal notice
Made & Powered by IMMA PUIG
Mallorca, 310 - 08037 Barcelona, Spain. Tel.: +34 93 207 59 20 - Fax: +34 93 457 66 42